Financial toxicity

Last updated

Financial toxicity describes the negative impact medical expenses can have on patients in terms of their health-related quality of life, [1] leading to negative mental and physical effects as well as, in some cases, bankruptcy, loss of job or income, or even homelessness. [2] [3] [4]

Contents

Background

The term financial toxicity was used in a 2009 article about the cancer drug industry "as a side effect of cancer drug treatment, along with nausea and hair loss". [5]

The cost of medical treatment has become a major complication of treatment in the United States, leading to suffering comparable to physical suffering and damaging a person's ability to recover from their illness, according to a 2013 study published in The Oncologist Journal. [6] Patients can forgo treatments or opt for less-cost treatments, which can have a negative impact on their health. [7]

Prevalence

In a study from Oregon, almost 20% of older adults with advanced cancer experienced financial toxicity. [8] This was assessed using 3 simple questions: "At any time in the past 3 months have you taken less medication than was prescribed for you because of the cost?" (Delayed medications); the second question was, "When you think about the amount of income that you have available in a typical month, is there enough for your food and housing costs?" (income available) and the third question was, "When you think about the amount of income that you have available in a typical month, is it enough for things you really need like clothing, medicine, repairs to the home or transportation” (enough income). [8]

Risk factors

As of 2020, preexisting debt, prediagnosis conditions, type of employment like hourly versus salaried, and asset levels are "areas in need of further study" according to the National Cancer Institute. [9] Certain types of cancer treatments requiring daily attendance to a clinic or healthcare provider can increase the risk of financial toxicity on patients. [4] [10] [2] [11] [12]

Interventions

Since 2009, the American Society of Clinical Oncology has recommended ~ guidance on how healthcare professionals talk to patients about costs. [13] Providing financial information, and counseling of the patient with "financial navigators" have been suggested. However, cancer treatment cost information is transparent. [9] [14]

Increasing insurance accessibility and putting trauma-informed treatment practices in place, with the result that health insurance helps lessen financial toxicity. [15]

See also

Related Research Articles

<span class="mw-page-title-main">Brachytherapy</span> Type of radiation therapy

Brachytherapy is a form of radiation therapy where a sealed radiation source is placed inside or next to the area requiring treatment. Brachy is Greek for short. Brachytherapy is commonly used as an effective treatment for cervical, prostate, breast, esophageal and skin cancer and can also be used to treat tumours in many other body sites. Treatment results have demonstrated that the cancer-cure rates of brachytherapy are either comparable to surgery and external beam radiotherapy (EBRT) or are improved when used in combination with these techniques. Brachytherapy can be used alone or in combination with other therapies such as surgery, EBRT and chemotherapy.

<span class="mw-page-title-main">Proton therapy</span> Medical Procedure

In medicine, proton therapy, or proton radiotherapy, is a type of particle therapy that uses a beam of protons to irradiate diseased tissue, most often to treat cancer. The chief advantage of proton therapy over other types of external beam radiotherapy is that the dose of protons is deposited over a narrow range of depth; hence in minimal entry, exit, or scattered radiation dose to healthy nearby tissues.

<span class="mw-page-title-main">Radiosurgery</span> Surgical Specialty

Radiosurgery is surgery using radiation, that is, the destruction of precisely selected areas of tissue using ionizing radiation rather than excision with a blade. Like other forms of radiation therapy, it is usually used to treat cancer. Radiosurgery was originally defined by the Swedish neurosurgeon Lars Leksell as "a single high dose fraction of radiation, stereotactically directed to an intracranial region of interest".

<span class="mw-page-title-main">Multileaf collimator</span>

A multileaf collimator (MLC) is a Collimator or beam-limiting device that is made of individual "leaves" of a high atomic numbered material, usually tungsten, that can move independently in and out of the path of a radiotherapy beam in order to shape it and vary its intensity.

<span class="mw-page-title-main">Radiation treatment planning</span> In cancer or tumor treatments

In radiotherapy, radiation treatment planning (RTP) is the process in which a team consisting of radiation oncologists, radiation therapist, medical physicists and medical dosimetrists plan the appropriate external beam radiotherapy or internal brachytherapy treatment technique for a patient with cancer.

<span class="mw-page-title-main">Tomotherapy</span> Type of radiation therapy

Tomotherapy is a type of radiation therapy treatment machine. In tomotherapy a thin radiation beam is modulated as it rotates around the patient, while they are moved through the bore of the machine. The name comes from the use of a strip-shaped beam, so that only one “slice” of the target is exposed at any one time by the radiation. The external appearance of the system and movement of the radiation source and patient can be considered analogous to a CT scanner, which uses lower doses of radiation for imaging. Like a conventional machine used for X-ray external beam radiotherapy, a linear accelerator generates the radiation beam, but the external appearance of the machine, the patient positioning, and treatment delivery is different. Conventional linacs do not work on a slice-by-slice basis but typically have a large area beam which can also be resized and modulated.

A dose-volume histogram (DVH) is a histogram relating radiation dose to tissue volume in radiation therapy planning. DVHs are most commonly used as a plan evaluation tool and to compare doses from different plans or to structures. DVHs were introduced by Michael Goitein and Verhey in 1979. DVH summarizes 3D dose distributions in a graphical 2D format. In modern radiation therapy, 3D dose distributions are typically created in a computerized treatment planning system (TPS) based on a 3D reconstruction of a CT scan. The "volume" referred to in DVH analysis is a target of radiation treatment, a healthy organ nearby a target, or an arbitrary structure.

<span class="mw-page-title-main">Prostate brachytherapy</span> Radiation therapy technique for the treatment of cancer

Brachytherapy is a type of radiotherapy, or radiation treatment, offered to certain cancer patients. There are two types of brachytherapy – high dose-rate (HDR) and low dose-rate (LDR). LDR brachytherapy is the one most commonly used to treat prostate cancer. It may be referred to as 'seed implantation' or it may be called 'pinhole surgery'.

"The Radiation Therapy Oncology Group (RTOG) was initially organized in 1968 under the direction of Simon Kramer as a national cooperative group for the purpose of conducting radiation therapy research and clinical investigations in order to treat cancers, including endometrial and cervical cancer. Funding from the National Cancer Institute (NCI) began in 1971.

<span class="mw-page-title-main">HPV-positive oropharyngeal cancer</span> Cancer of the throat

Human papillomavirus-positive oropharyngeal cancer, is a cancer of the throat caused by the human papillomavirus type 16 virus (HPV16). In the past, cancer of the oropharynx (throat) was associated with the use of alcohol or tobacco or both, but the majority of cases are now associated with the HPV virus, acquired by having oral contact with the genitals of a person who has a genital HPV infection. Risk factors include having a large number of sexual partners, a history of oral-genital sex or anal–oral sex, having a female partner with a history of either an abnormal Pap smear or cervical dysplasia, having chronic periodontitis, and, among men, younger age at first intercourse and a history of genital warts. HPV-positive OPC is considered a separate disease from HPV-negative oropharyngeal cancer.

The term radiogenomics is used in two contexts: either to refer to the study of genetic variation associated with response to radiation or to refer to the correlation between cancer imaging features and gene expression.

Wolfgang Axel Tomé is a physicist working in medicine as a researcher, inventor, and educator. He is noted for his contributions to the use of photogrammetry in high precision radiation therapy; his work on risk adaptive radiation therapy which is based on the risk level for recurrence in tumor sub-volumes using biological objective functions; and the development of hippocampal avoidant cranial radiation therapy techniques to alleviate hippocampal-dependent neurocognitive impairment following cranial irradiation.

Sandro Porceddu is a head and neck radiation oncologist at Brisbane's Princess Alexandra Hospital and a Professor with the University of Queensland. He was president of the Clinical Oncologic Society of Australia (COSA) and chair of the Trials Scientific Committee of the Trans Tasman Radiation Oncology Group (TROG).

Eleanor D. Montague was an American radiologist and educator who established breast-conserving therapy in the United States and improved radiation therapy techniques. She became a member of the Texas Women's Hall of Fame in 1993.

<span class="mw-page-title-main">Deep inspiration breath-hold</span> Method of delivering radiotherapy

Deep inspiration breath-hold (DIBH) is a method of delivering radiotherapy while limiting radiation exposure to the heart and lungs. It is used primarily for treating left-sided breast cancer.

<span class="mw-page-title-main">Daniel Przybysz</span> Brazilian radiation oncologist

Dr. Daniel Przybysz is a Brazilian Radiation-Oncologist. His practice is mainly focused on lung cancer treatment and high technology approaches toward better patient care

Edward C. Halperin, is the chancellor and CEO of New York Medical College (NYMC) where he is also a professor of radiation medicine, pediatrics and history. He also serves as the Miriam Popack Chair in Biomedical Ethics and director of the Hirth and Samowitz Center for Medical Humanities and Holocaust Studies at NYMC, director of bioethics in the School of Health Sciences and Practice at NYMC, as well as provost for biomedical affairs for the Touro College and University System, a position he has held since 2012.

<span class="mw-page-title-main">Nabil F. Saba</span> Atlanta oncologist

Nabil F. Saba is an American oncologist. He is currently Professor and Vice-chair of Hematology and Medical Oncology, and Professor of Otolaryngology at the Winship Cancer Institute at the Emory University School of Medicine in Atlanta, Georgia. He is a specialist in the field of head and neck oncology. Saba has authored more than 200 peer-reviewed articles. He is the inaugural Lynne and Howard Halpern Chair in Head and Neck Cancer Research.

Herman Day Suit was an American physician and radiation oncologist. Suit is a pioneer in precision radiotherapy and proton therapy for cancer.

FLASH radiotherapy is an emerging form of radiotherapy which delivers a high dose of radiation to the patient in an ultra-short time frame which produces a tumour killing effect comparable to conventional radiotherapy but with less damage to surrounding healthy tissue. The treatment is in the early stages of development and is not yet widely available as a form of cancer therapy.

References

  1. ↑ Khera R, Valero-Elizondo J, Nasir K (October 2020). "Financial Toxicity in Atherosclerotic Cardiovascular Disease in the United States: Current State and Future Directions". Journal of the American Heart Association. 9 (19): e017793. doi: 10.1161/JAHA.120.017793 . PMC   7792407 . PMID   32924728.
  2. 1 2 Patel, T.; Keith, S.; Eldredge-Hindy, H.; Fisher, S.A.; Palmer, J.D. (2019-09-01). "Development of a Financial Toxicity Screening Tool for Radiation Oncology: A Secondary Analysis of a Prospective PROs Study". International Journal of Radiation Oncology, Biology, Physics. 105 (1): E589–E590. doi:10.1016/j.ijrobp.2019.06.1184. ISSN   0360-3016.
  3. ↑ Palmer, Joshua D.; Patel, Tejash T.; Eldredge-Hindy, Harriet; Keith, Scott W.; Patel, Tapas; Malatesta, Theresa; DiNome, Jessie; Lowther, Anne; Ferguson, Linda; Wagenborg, Sally; Smyles, John (2018-06-01). "Patients Undergoing Radiation Therapy Are at Risk of Financial Toxicity: A Patient-based Prospective Survey Study". International Journal of Radiation Oncology, Biology, Physics. 101 (2): 299–305. doi:10.1016/j.ijrobp.2018.03.014. ISSN   0360-3016.
  4. 1 2 Prasad, Rahul N.; Royce, Trevor J.; Chino, Fumiko; Jagsi, Reshma; Palmer, Joshua D. (2022-11-30). "Financial Toxicity as an End Point in Prospective Clinical Trials Involving Radiation Therapy". Advances in Radiation Oncology. 7 (6): 100970. doi:10.1016/j.adro.2022.100970. ISSN   2452-1094. PMC   9126781 . PMID   35620674.
  5. ↑ Pollack, Andrew (2009-09-02). "For Profit, Industry Seeks Cancer Drugs (Published 2009)". The New York Times. ISSN   0362-4331 . Retrieved 2021-01-13.
  6. ↑ Ali McBride, Lisa M. Holle, Colleen Westendorf, Margaret Sidebottom, Niesha Griffith, Raymond J. Muller, James M. Hoffman, National survey on the effect of oncology drug shortages on cancer care, American Journal of Health-System Pharmacy, Volume 70, Issue 7, 1 April 2013, Pages 609–617, doi : 10.2146/ajhp120563
  7. ↑ Dr Yousuf Zafar Explains How Financial Toxicity Impacts Cancer Patients , retrieved 2023-10-06
  8. 1 2 Arastu, Asad; Patel, Arpan; Mohile, Supriya Gupta; Ciminelli, Joseph; Kaushik, Ramya; Wells, Megan; Culakova, Eva; Lei, Lianlian; Xu, Huiwen; Dougherty, David W.; Mohamed, Mostafa R. (2020-12-07). "Assessment of Financial Toxicity Among Older Adults With Advanced Cancer". JAMA Network Open. 3 (12): e2025810. doi: 10.1001/jamanetworkopen.2020.25810 . ISSN   2574-3805. PMC   8184122 . PMID   33284337.
  9. 1 2 "Financial Toxicity and Cancer Treatment–Health Professional Version - National Cancer Institute". www.cancer.gov. 2016-08-26. Retrieved 2021-01-13.
  10. ↑ Wages, Nolan A.; Sanders, Jason C.; Smith, Amy; Wood, Songserea; Anscher, Mitchell S.; Varhegyi, Nikole; Krupski, Tracey L.; Harris, Timothy J.; Showalter, Timothy N. (2021-04-01). "Hypofractionated Postprostatectomy Radiation Therapy for Prostate Cancer to Reduce Toxicity and Improve Patient Convenience: A Phase 1/2 Trial". International Journal of Radiation Oncology, Biology, Physics. 109 (5): 1254–1262. doi:10.1016/j.ijrobp.2020.11.009. ISSN   0360-3016. PMC   7965239 . PMID   33227441.
  11. ↑ Johnstone, Gregory P.; Johnstone, Peter A.S. (2018-06-01). "The Oncologist's Role in Managing Financial Toxicity". International Journal of Radiation Oncology, Biology, Physics. 101 (2): 306–308. doi:10.1016/j.ijrobp.2017.11.046. ISSN   0360-3016.
  12. ↑ Palmer, Joshua D.; Patel, Tejash T.; Eldredge-Hindy, Harriet; Keith, Scott W.; Patel, Tapas; Malatesta, Theresa; DiNome, Jessie; Lowther, Anne; Ferguson, Linda; Wagenborg, Sally; Smyles, John (2018-07-15). "Patients Undergoing Radiation Therapy Are at Risk of Financial Toxicity: A Patient-based Prospective Survey Study". International Journal of Radiation Oncology, Biology, Physics. 101 (2): 299–305. doi:10.1016/j.ijrobp.2018.03.014. ISSN   0360-3016.
  13. ↑ Meropol, Neal J.; Schrag, Deborah; Smith, Thomas J.; Mulvey, Therese M.; Langdon, Robert M.; Blum, Diane; Ubel, Peter A.; Schnipper, Lowell E. (2009-08-10). "American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care". Journal of Clinical Oncology. 27 (23): 3868–3874. doi: 10.1200/JCO.2009.23.1183 . PMID   19581533 . Retrieved 2021-01-13.
  14. ↑ Lentz, Robert; Benson, Al B.; Kircher, Sheetal (July 2019). "Financial toxicity in cancer care: Prevalence, causes, consequences, and reduction strategies". Journal of Surgical Oncology. 120 (1): 85–92. doi:10.1002/jso.25374. ISSN   0022-4790.
  15. ↑ Chervu, Nikhil; Branche, Corynn; Verma, Arjun; Vadlakonda, Amulya; Bakhtiyar, Syed Shahyan; Hadaya, Joseph; Benharash, Peyman (2023-06-01). "Association of insurance status with financial toxicity and outcome disparities after penetrating trauma and assault". Surgery. 173 (6): 1493–1498. doi:10.1016/j.surg.2023.02.033. ISSN   0039-6060.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.